New Insights Into the Biological Activity Evaluation of Mango Juices Processed by Sustainable Emerging Technologies

Condition(s) studied

Investigational drug(s) / intervention(s)

HPP mango juice group: During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon

control juice: During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon

Study summary

The aim of this clinical trial is to study the effect of a habitual dietary intake of commercial high pressure-processed (HPP) mango juice \[mango puree (20%)-orange juice (80%)\] or control juice \[water (20%)-HPP orange juice (80%)\]. There are numerous in vitro and in vivo animal studies that support exceptional health-promoting characteristics of mango products (pulp, peel, seed, juice, extracts, etc.) such as antidiabetic, anticancer, antiinflammatory, antioxidant and antibacterial activities based on their phytochemical composition, but there are many fewer studies assessing the absorption, metabolism, and health-related properties of phytochemical from commercial mango fruit juices (only 20% of mango pulp) in humans. Consequently, this study proposes for the first time the study of the effects of commercial HPP mango juice consumption on health biomarkers by a human intervention study. Researchers will compare the bioavailability (metabolite profiles) of compounds with health effects and the biomarkers of health to evaluate if mango juice works better that control juice.

Eligibility

Primary outcome measure(s)

• C-Reactive Protein (CRP) — At Week 0 (day 0-Baseline), and Weeks 2 (day 14), and 4 (day 28)
  Changes of plasma CRP levels as result of HPP mango juice intake

Trial sites (1)

More National Research Council, Spain trials in Spain